SLC5A1 and cystic fibrosis: In sum, we report the establishment of PSC-derived isogenic CF HLOs, demonstrate the use of these HLOs for evaluating the effects of both FDA-approved and investigational compounds, and reveal SGLTs, especially SGLT1, as potential drug targets for treating CF lung diseases.